Boston Scientific (MEX:BSX) Cyclically Adjusted Revenue per Share: MXN183.69 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BSX Boston Scientific Corp MEX:BSX
78 GF Score
Price MXN794.49
GF Value MXN1,833.75
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific Cyclically Adjusted Revenue per Share?

Boston Scientific MEX:BSX +0.21% 78 Cyclically Adjusted Revenue per Share is MXN183.69 as of Jun. 2026. GuruFocus rates MEX:BSX with a GF Score™ of 78/100 and a GF Value™ of MXN1,833.75 (Significantly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Boston Scientific's adjusted revenue per share for the three months ended in Jun. 2026 was MXN64.387. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN183.69 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Boston Scientific's average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Boston Scientific was 16.80% per year. The lowest was -2.90% per year. And the median was 5.70% per year.

As of today (2026-08-30), Boston Scientific's current stock price is MXN794.49. Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN183.69. Boston Scientific's Cyclically Adjusted PS Ratio of today is 4.33.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boston Scientific was 11.69. The lowest was 3.51. And the median was 6.07.


Boston Scientific  (MEX:BSX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Boston Scientific's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=794.49/183.69
=4.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boston Scientific was 11.69. The lowest was 3.51. And the median was 6.07.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Boston Scientific Cyclically Adjusted Revenue per Share Related Terms


Boston Scientific Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Cyclically Adjusted Revenue per Share Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.98 157.84 138.55 187.05 178.95

Boston Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179.18 179.29 178.95 182.90 183.69

MEX:BSX vs EW, DXCM, GEHC: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cyclically Adjusted PS Ratio falls into.


MEX:BSX
78GF Score
Boston Scientific Corp MEX:BSX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Boston Scientific's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=64.387/333.9520*333.9520
=64.387

Current CPI (Jun. 2026) = 333.9520.

Boston Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 29.500 241.428 40.805
201612 32.636 241.432 45.143
201703 29.255 243.801 40.073
201706 29.328 244.955 39.983
201709 28.925 246.819 39.136
201712 33.891 246.524 45.910
201803 30.943 249.554 41.408
201806 34.976 251.989 46.352
201809 31.883 252.439 42.178
201812 35.760 251.233 47.534
201903 34.336 254.202 45.108
201906 35.879 256.143 46.778
201909 37.843 256.759 49.220
201912 38.753 256.974 50.362
202003 42.185 258.115 54.579
202006 32.769 257.797 42.449
202009 41.051 260.280 52.670
202012 37.742 260.474 48.389
202103 39.316 264.877 49.569
202106 42.758 271.696 52.556
202109 41.995 274.310 51.126
202112 44.665 278.802 53.500
202203 41.887 287.504 48.654
202206 45.391 296.311 51.157
202209 44.281 296.808 49.823
202212 43.811 296.797 49.296
202303 42.245 301.836 46.740
202306 42.371 305.109 46.376
202309 41.652 307.789 45.193
202312 42.818 306.746 46.616
202403 43.190 312.332 46.180
202406 50.855 314.175 54.056
202409 55.719 315.301 59.015
202412 63.837 315.605 67.548
202503 63.892 319.799 66.720
202506 63.806 322.561 66.059
202509 62.129 324.800 63.880
202512 63.622 324.054 65.565
202603 62.759 330.213 63.470
202606 64.387 333.952 64.387

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN183.69 mean?
Boston Scientific (MEX:BSX) has a Cyclically Adjusted Revenue per Share of MXN183.69 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Boston Scientific and its competitors.
Is Boston Scientific's Cyclically Adjusted Revenue per Share too high?
Boston Scientific's current Cyclically Adjusted Revenue per Share is MXN183.69. Overall, Boston Scientific has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Cyclically Adjusted Revenue per Share compare to EW and DXCM?
Boston Scientific's Cyclically Adjusted Revenue per Share of MXN183.69 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Boston Scientific and its competitors. Boston Scientific's current Cyclically Adjusted Revenue per Share is MXN183.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,833.75, compared to a current price of MXN794.49 — trading 56.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN183.69. Boston Scientific's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current Cyclically Adjusted Revenue per Share is MXN183.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (MEX:BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of MXN794.49 is trading 56.7% below its estimated GF Value™ of MXN1,833.75. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for MEX:BSX:

  • Cyclically Adjusted Revenue per Share: MXN183.69
  • GF Value™: MXN1,833.75 vs. price of MXN794.49 (56.7% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
78GF Score

Get the complete analysis for MEX:BSX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN794.49
Price
MXN1,833.75
GF Value